The tweet was deleted by the author.
But we saved everything 🙂.
CVRx announced that Dr. Savitri Fedson has shared a real-world account highlighting the impact of Barostim therapy on heart failure patients.
According to Dr. Fedson, patients using Barostim have experienced notable improvements in their quality of life, underscoring the growing role of neuromodulation therapy in addressing chronic heart failure conditions.
CVRx previously forecast first-quarter 2026 revenue of $14.7 million to $14.8 million, representing an estimated 20 percent rise from the prior year period, according to preliminary results. The company also held a dedicated session on Barostim and neurohormonal targeting at ISHLT2026, focusing on innovations in heart failure treatment during the event. These initiatives reflect CVRx’s continued emphasis on Barostim’s therapeutic potential and commercial growth.